EuBiologics, a Korean vaccine developer, is deepening its financial commitment to its American subsidiary, EuPOP Life Sciences Inc. The company announced Wednesday that it has injected $10 million, or approximately 13.8 billion won, into the venture. This capital infusion is part of a strategy to acquire an additional 8,750 newly issued shares, raising the parent company’s total stake to 15,000 shares. Upon completion of this transaction, EuBiologics will control 80 percent of EuPOP, giving it a dominant position in the U.S. joint venture.
EuBiologics Tightens Control of Subsidiary
The investment is designed to support continued research and development within EuPOP’s pipeline. EuBiologics plans to use the funds to strengthen its control over the subsidiary and ensure that clinical programs do not face financial bottlenecks. By purchasing the additional shares through a third-party allotment, EuBiologics effectively consolidates its equity. This move suggests a desire to streamline decision-making processes within the U.S. entity, moving away from potential complexities that can arise from holding a minority interest in a high-growth biotechnology company.
Related: How Emsculpt Neo Helps You Achieve Full-Body Toning
EuPOP Life Sciences is a joint venture established between EuBiologics and Pop Biotechnologies, a U.S.-based biotechnology firm. The subsidiary is currently focused on developing vaccines against respiratory syncytial virus (RSV), shingles, and Alzheimer’s disease. The company is employing a dual-technology approach, combining EuBiologics’ EuIMT immune-enhancing technology with Pop Biotechnologies’ SNAP nanoparticle-based antigen delivery system. This combination of technologies aims to create a more effective immune response for complex diseases.
Advancing Clinical Trials
Beyond the financial injection, EuPOP is actively advancing its clinical pipeline. The company recently filed an Investigational New Drug (IND) application to initiate a phase 1 clinical trial for its Alzheimer’s therapeutic vaccine. It is also pursuing a follow-up clinical trial for its shingles vaccine. These filings are critical steps that mark the transition of these vaccine candidates from preclinical research into human testing. The focus on these three areas—RSV, shingles, and Alzheimer’s—highlights the company’s ambition to address major unmet medical needs.
Pop Biotechnologies brings significant experience to the partnership, having conducted vaccine research with organizations including the U.S. National Institutes of Health (NIH). The company recently secured up to $9.7 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI). This external capital was designated to support the clinical development of the SNAP platform and related programs. The backing from CEPI reinforces the technical viability of the delivery technology used by the subsidiary.
Related: Hazelwood’s Sparkling Secrets: Where Love Meets Luxury
EuBiologics plans to develop EuPOP Life Sciences into a global hub for clinical development and business development of premium vaccines. The parent company intends to leverage the clinical progress in its key pipeline programs to pursue licensing deals, co-development partnerships, and fundraising with global pharmaceutical and biotechnology companies. In the longer term, EuBiologics has expressed plans to pursue a Nasdaq listing for EuPOP Life Sciences.
“This investment is intended to enhance the global competitiveness of the premium vaccines being developed through EuPOP Life Sciences and accelerate their clinical development and commercialization,” a EuBiologics official said. The official added, “We will continue to increase EuPOP Life Sciences’ corporate value by translating progress in the EuIMT- and SNAP-based pipeline into global licensing and commercialization opportunities.”